Search Results
Oct 14, 2025, 08:30 ET Caris Life Sciences to Share Six Collaborative Studies at ESMO 2025
Impact of Androgen Deprivation Therapy (ADT) on KLK2 mRNA Expression and Immunologic Correlates Across Prostate Cancer Disease States (Presentation Number: 2437P)Saturday, Oct 18, 2025
More news about: Caris Life Sciences
Oct 14, 2025, 02:50 ET Waters、次世代バイオ治療薬の開発を加速するための電荷検出質量分析技術を発表
Waters Xevo Charge Detection Mass Spectrometer（電荷検出質量分析計、以下CDMS）を発表しました。細胞・遺伝子治療、mRNA、および複雑なタンパク質治療薬の急速な発展に伴い、研究者はますます巨大かつ不均一な医薬品モダリティの解析において重大な課題に直面しています。しかし、既存の分析ツールは分解能、感度、そしてコンプライアンス対応の点で限界がありました。Xevo CDMSシステムは、最大150メガダルトン（MDa）を超える分子を対象に、粒子単位で直接質量を測定することで、これらの課題を解決します。これにより、これまで解析が困難であったタンパク質複合体、核酸、脂質ナノ粒子、ウイルスベクターなどの詳細な分析が可能になります。
More news about: Waters Corporation
Oct 13, 2025, 20:00 ET Waters推出全新電荷檢測質譜技術，加速新一代生物治療藥物研發進程
Waters公司（紐約證券交易所代碼：WAT）今日隆重推出 Waters™ Xevo CDMS 電荷檢測質譜儀，為新一代治療藥物與結構生物學領域中具有核心地位的超大質量生物大分子，提供一款涵蓋範圍廣、性能卓越的測量與表徵工具。隨著細胞與基因療法、mRNA 以及複雜蛋白質類治療藥物的迅速發展，科學家在分析日益龐大且異質性更強的藥物形式時面臨巨大挑戰，而現有工具在解析度、靈敏度與合規性方面存在諸多限制。Xevo
More news about: Waters Corporation
Oct 13, 2025, 11:20 ET Nanomedicine Market Size to Reach US$ 389.52 Billion by 2033, Driven by Advancements in Targeted Therapies and Drug Delivery Innovations | According DataM Intelligence
CAGR of 9.7% during the forecast period 2025-2033, driven by rising chronic diseases, demand for targeted therapies, and advancements in drug delivery, mRNA vaccines, and gene editing.
More news about: DataM Intelligence 4 Market Research LLP
Oct 13, 2025, 08:05 ET Waters Launches Charge Detection Mass Spectrometry Technology to Accelerate the Development of Next-Generation Biotherapeutics
broadest range of mega-mass biomolecules central to next-generation therapeutics and structural biology. With the rapid growth of cell and gene therapies, mRNA, and complex protein therapeutics, scientists face significant challenges in analyzing increasingly large and heterogeneous drug modalities – yet existing
More news about: Waters Corporation
Oct 13, 2025, 08:05 ET Waters Launches Charge Detection Mass Spectrometry Technology to Accelerate the Development of Next-Generation Biotherapeutics
broadest range of mega-mass biomolecules central to next-generation therapeutics and structural biology. With the rapid growth of cell and gene therapies, mRNA, and complex protein therapeutics, scientists face significant challenges in analyzing increasingly large and heterogeneous drug modalities – yet existing
More news about: Waters Corporation
Oct 09, 2025, 08:30 ET Simplifying CRISPR Therapeutic Manufacturing: Practical Solutions to Accelerate and Simplify Manufacturing, Upcoming Webinar Hosted by Xtalks
vendor cycle times and slot alignment. The featured speakers will share practical strategies to reduce delays and improve efficiency across sgRNA, pDNA, mRNA, LNP and fill/finish workflows. The speakers will discuss how integration across development and manufacturing can strengthen regulatory submissions
More news about: Xtalks
Oct 09, 2025, 07:00 ET Samsung Biologics Introduces Optimized Manufacturing Framework, ExellenS™
cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics. By implementing the ExellenSTM framework across its manufacturing network with standardized
More news about: Samsung Biologics
Oct 08, 2025, 17:31 ET Hereditary Transthyretin Amyloidosis Market Forecasts Strong Growth Amid New Treatment Launches | DelveInsight
disease. Gene-silencing agents, such as eplontersen (WAINUA), patisiran (ONPATTRO), and inotersen (TEGSEDI), act by suppressing TTR mRNA in the liver, thereby reducing the production of both mutant and normal transthyretin proteins and slowing disease progression through lowered circulating
More news about: DelveInsight Business Research, LLP
Oct 08, 2025, 08:30 ET ImmunoVec Launches from Stealth with up to $40.7 Million ARPA-H EMBODY Award to Advance In Vivo Cell Engineering Platform for Autoimmune Diseases
safer and more flexible manufacturing process. In parallel, its DNA-based payload enables durable, long-term expression, a key advantage over transient mRNA systems. This dual-regulation strategy has the potential to provide unprecedented control, therapeutic efficacy, and safety by ensuring genetic therapies
More news about: ImmunoVec
Oct 08, 2025, 08:00 ET CREATE Medicines Strengthens Executive Team with Appointment of Veteran Biopharma Leader Allan L. Shaw as CFO and CBO
CREATE Medicines (formerly Myeloid Therapeutics) is a clinical-stage biotech pioneering in vivo multi-immune programming. Its proprietary mRNA-LNP platform directly programs immune cells inside the body to deliver scalable, repeat-dose, off-the-shelf immunotherapies. With proven human validation
More news about: CREATE Medicines, Inc.
Oct 07, 2025, 17:30 ET BIOVAXYS ANNOUNCES LIFE OFFERING
preclinical supply of DPX+peanut antigen for the peanut allergy vaccine program, and additional proof of concept studies for expanding the DPX formulations in mRNA and neoantigens; (3) initiating DPX food allergy program at McMaster University for conducting a preclinical proof of concept study with a DPX peanut
More news about: BioVaxys Technology Corp.
Oct 07, 2025, 11:00 ET Rare Disease Therapeutics Market to Surpass US$ 495.27 Billion by 2033 as Gene Therapy, RNA-based Drugs, and Biologics Transform Patient Care
RNA-based Therapies, valued at US$ 26 billion in 2024, are gaining rapid adoption following the success of mRNA vaccines. Companies such as Sarepta and Alnylam are expanding RNA-based pipelines in neuromuscular and metabolic disorders.
More news about: DataM Intelligence 4 Market Research LLP
Oct 07, 2025, 08:00 ET RheumaGen and SiVEC Biotechnologies Announce CGT Partnership and In Vivo Program to Cure Common Autoimmune Diseases
achieving safe, targeted delivery with the added advantage of simple, scalable manufacturing. BactPac delivers a diverse array of biologics, including mRNA, siRNA, proteins, and CRISPR gene editors, with precision and safety that surpass traditional delivery methods. SiVEC's lead therapeutic, SVC-KRAb™,
More news about: RheumaGen, Inc.
Oct 07, 2025, 07:00 ET Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment
"The successful transfer of our EU marketing authorization to Sanofi is yet another step forward in ensuring global access to our protein-based, non-mRNA COVID-19 vaccine." Novavax is eligible to receive additional future milestones and royalties under the CLA related to Nuvaxovid,
More news about: Novavax, Inc.
Oct 07, 2025, 03:30 ET Resolution Therapeutics to present EMERALD study design at the British Association for the Study of the Liver (BASL) annual meeting 2025
autologous regenerative macrophage therapy with enhanced anti-fibrotic and anti-inflammatory effects. The product candidate is engineered with IL-10-MMP9 mRNA to enhance the natural regenerative properties of macrophages for superior efficacy and durability. RTX001 is being tested in the Phase I/II study called
More news about: Resolution Therapeutics
Oct 06, 2025, 11:03 ET Wasatch BioLabs Expands Service Portfolio with Oxford Nanopore Assays in Pharmacogenomics, Telomere Sequencing, and mRNA Vaccine Quality Control
consistency. mRNA Vaccine Quality ControlWith long reads, single-molecule resolution, and no amplification artifacts, Wasatch BioLab's mRNA Vaccine QC service delivers a complete and accurate view of mRNA constructs, from early development through lot release
More news about: Wasatch BioLabs
Oct 06, 2025, 08:30 ET Novel Long RNA Manufacturing Approaches for Advancing RNA Therapeutics, Upcoming Webinar Hosted by Xtalks
100-base-length RNAs with chemical modifications partially. Furthermore, a 560 base length mRNA encoding a protein was successfully synthesized, and a functional protein was synthesized by a cell-free translation system using this mRNA. This solution for the production of long-stranded RNA allows
More news about: Xtalks
Oct 06, 2025, 08:00 ET Myeloid Therapeutics Rebrands as CREATE Medicines, Focused on Transforming Immunotherapy Through RNA-Based In Vivo Multi-Immune Programming
integration via RNA-based retrotransposon technology. Industry-leading RNA: Up to 8+ days of linear mRNA expression with no reactogenicity. Speed and scalability: Concept-to-clinic in <12 months
More news about: CREATE Medicines, Inc.
Oct 01, 2025, 09:01 ET Primrose Bio Names Drew Burch as CEO
enzymes for mRNA manufacturing; and PeliCRM197®: a commercially validated
More news about: Primrose Bio
Oct 01, 2025, 09:01 ET Laguna Diagnostics Awarded Second U.S. Patent for Rapid Blood Tests to Differentiate Schizophrenia and Bipolar Disorder, Expanding IP Portfolio in $3B Market
psychiatrically normal individuals (NC). The method comprises: a) Precision Biomarker Signatures determining the mRNA* gene expression level of 18 genes;b) proceeds in a four-step process;c) calculating the probability that a sample comes from a subject
More news about: Laguna Diagnostics, LLC
Oct 01, 2025, 09:00 ET Turning Awareness Into Action: American Cancer Society Recognizes 40 Years of Breast Cancer Awareness Month
Triple-negative breast cancer immunotherapy approved 2020s mRNA-based breast cancer vaccines show promise, and liquid biopsies projected to expand Despite these breakthroughs
More news about: American Cancer Society
Oct 01, 2025, 08:53 ET Mercury Bio Reports Positive Results from Preclinical Study Evaluating Novel Drug Delivery Technology Transporting Protein Cargo to the Brain
drug candidates aimed at treating brain diseases. While there have been considerable strides in developing biologic-based treatments—such as proteins, mRNA, or antibodies—for neurodegenerative disorders, most are not clinically viable because there has been no reliable, scalable means of transporting such
More news about: Mercury Bio Inc.
Oct 01, 2025, 06:00 ET PhotonPharma Inc. CEO to Present Novel Autologous Treatment Platform at Premier Cancer Immunotherapy Conference
from industry leaders including Moderna, Merck, BioNTech, and Genentech, alongside innovative companies developing next-generation platforms across mRNA, peptide, viral, and cellular modalities. About PhotonPharma PhotonPharma
More news about: PhotonPharma Inc.
Sep 29, 2025, 10:18 ET METiS Launches World's First AI-Driven Nano-Delivery Platform NanoForge
infrastructure and predictive accuracy. Built on this platform are three core solutions: AiLNP (AI Nucleic Acid Delivery Design), AiRNA (AI mRNA Sequence Design), and AiTEM (AI Small Molecule Formulation Design). To date, METiS has built a library of over 10 million
More news about: METiS TechBio